Important Notice for Geron Corporation Shareholders
New York, April 3, 2025 – The Gross Law Firm, a leading national securities fraud class action law firm, notifies investors of a class action lawsuit against Geron Corporation (NASDAQ: GERN). Investors who purchased shares of Geron during the class period listed below are encouraged to contact the firm regarding possible lead plaintiff appointment:
Class Period:
The class period begins on January 1, 2023, and ends on December 31, 2024.
Allegations:
The complaint alleges that Geron Corporation and certain of its officers and directors violated the Securities Exchange Act of 1934 and securities laws by making false and misleading statements and failing to disclose material information to the investing public. Specifically, the complaint alleges that the defendants made false statements regarding the commercial prospects of Geron’s telomerase inhibitor, Imetelstat, and the company’s financial condition.
Lead Plaintiff Appointment:
If you purchased shares of Geron Corporation during the class period and wish to serve as lead plaintiff, you must move the Court no later than March 22, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Contact Information:
Shareholders who purchased shares of Geron Corporation during the class period can contact The Gross Law Firm at 888-440-09-10, via email at [[email protected]](mailto:[email protected]), or through their website, to discuss their legal rights and potential remedies. The firm takes all cases on contingency and offers free consultations.
Impact on Individual Investors
If you purchased Geron Corporation shares during the class period and have experienced significant losses, this lawsuit may provide you with an opportunity to recover your damages. As a shareholder, you are a crucial part of the corporate world, and you have the right to be informed of any material information that could impact the value of your investment. The Gross Law Firm is dedicated to ensuring that companies are held accountable for their actions and that investors are fairly compensated.
Impact on the Global Community
The securities fraud class action against Geron Corporation is not just an isolated incident. It is a reminder that the global financial market is complex and that investors must be vigilant in protecting their investments. The class action lawsuit serves as a deterrent to companies that may be considering engaging in fraudulent activities. It also sends a message that investors have a voice and that they can hold companies accountable for their actions. Furthermore, the lawsuit could lead to increased transparency and better corporate governance practices in the biotech industry.
Conclusion
The Gross Law Firm’s class action lawsuit against Geron Corporation serves as a reminder to investors of the importance of staying informed and vigilant when it comes to their investments. Shareholders who purchased Geron Corporation shares during the class period and have experienced significant losses are encouraged to contact the firm regarding possible lead plaintiff appointment. The lawsuit is not just an opportunity for individual investors to recover their damages but also a chance to hold a company accountable for its actions and contribute to the global effort to protect the integrity of the financial market. The case also highlights the importance of transparency and corporate governance practices in the biotech industry.
- Geron Corporation shareholders who purchased shares during the class period encouraged to contact The Gross Law Firm regarding lead plaintiff appointment
- Class period: January 1, 2023 – December 31, 2024
- Complaint alleges false statements and failure to disclose material information
- Individual investors may recover damages through the lawsuit
- Lawsuit serves as a deterrent to companies engaging in fraudulent activities
- Contributes to increased transparency and better corporate governance practices in the biotech industry
